Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 7,901–8,000 of 15,747
Shrestha, N. K. M., Burke, P. C., Nowacki, A. S., et al. (2024) · medRxiv · doi:10.1101/2024.04.27.24306378 · Cited by 8
“Although the original messenger RNA (mRNA) Coronavirus Disease 2019 (COVID-19) vaccines were highly effective early in the pandemic [1,2], their effectiveness decreased as the causative agent of COVID-19, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus, evolved over time and…”
BackgroundJiang, C., Jiang, K., Li, X., Zhang, N., Zhu, W., Meng, L., Zhang, Y., & Lu, S. (2022) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2022.10.003 · Cited by 8
Abbad, A., Yellin, T., Singh, G., Fried, M., Raskin, A. J., Tcheou, J., Monahan, B., Gleason, C., Andre, D., Bermúdez-González, M. C., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101474 · Cited by 9
Updates on Coronavirus Disease-2019 Vaccine and Consideration in Children
Kang, H. M., Choi, E. H., & Kim, Y. (2021) · Pediatric Infection & Vaccine · doi:10.14776/piv.2021.28.e6 · Cited by 8
Coronavirus disease vaccination in heart failure: No time to waste
Roncalli, J. G., Roubille, F., Lamblin, N., Girerd, N., Mouquet, F., Chapet, N., Roubille, C., Berthelot, E., Galois, K., Battistella, P., et al. (2021) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2021.04.004 · Cited by 10
Roberts, E., Gu, T., Wagner, A. L., Mukherjee, B., & Fritsche, L. G. (2022) · AJPM Focus · doi:10.1016/j.focus.2022.100015 · Cited by 9
Fantin, R., Herrero, R., Hildesheim, A., Barboza‐Solís, C., Aparicio, A., Prevots, D. R., Pfeiffer, R. M., Gail, M. H., & the RESPIRA Study Group (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07740-5 · Cited by 8
“For two doses, our estimates for incident COVID-19 are consistent with the findings in Israel [3], Canada [6], and with the randomized trial in the US and elsewhere [2], in view of the overlapping confidence intervals.”
BackgroundResultBorgonovo, F., Passerini, M., Piscaglia, M., Morena, V., Giacomelli, A., Oreni, L. M., Dedivitiis, G., Lupo, A., Falvella, S., Cossu, M. V., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.01.023 · Cited by 7
Fujimoto, K. J., Hobbs, D. C., Umeda, M., Nagata, A., Yamaguchi, R., Sato, Y., Sato, A., Ohmatsu, K., Ooi, T., Yanai, T., et al. (2022) · Viruses · doi:10.3390/v14020389 · Cited by 8
Giossi, R., Consonni, A., Clerici, V. T., et al. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103415 · Cited by 8
Further implications on the global real-world vaccine effectiveness against SARS-CoV-2
Solante, R., Álvarez, C., Burhan, E., et al. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2110073 · Cited by 8
Analysis of COVID-19 on Diagnosis, Vaccine, Treatment, and Pathogenesis with Clinical Scenarios
Tellez, D., Dayal, S., Phan, P., Mawley, A., Shah, K., Consunji, G., Tellez, C., Ruiz, K., Sabnis, R., Dayal, S., et al. (2021) · Clinics and Practice · doi:10.3390/clinpract11020044 · Cited by 8
“Pfizer’s vaccine is called BNT162b2 and is a lipid nanoparticle-formulated mRNA vaccine that encodes the spike protein [8].”
BackgroundVerde, N. M. L., Riva, A., Cona, M. S., Gabrieli, A., Cattaneo, M., Fasola, C., Lipari, G., Stradis, C. D., Favorito, V., Stocchetti, B. L., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34273 · Cited by 9
“Nevertheless, the results are consistent with the literature data regarding seroconversion in the general population.(17,18) Our study enriches the current knowledge regarding the immunogenicity of BNT162b2 and mRNA-1273 in patients with cancer with or without a previous exposure to the virus, exploring it in the earl…”
Shapiro, L. C., Thakkar, A., Gali, R., Gonzalez‐Lugo, J. D., Bazarbachi, A. H., Rahman, S., Pradhan, K., Fehn, K., Abreu, M., Kornblum, N. S., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2074988 · Cited by 8
“Johnson) vaccine have robust safety and efficacy against COVID-19 among immunocompetent individuals, however, patients with cancer were not enrolled in these registration trials.(3-5) Emerging evidence suggests that despite the three COVID-19 vaccines with emergency use authorization (EUA) by the FDA inducing high lev…”
BackgroundAbdelgawad, F. A. M., El‐Hawary, S. S., El-Kader, E. M. A., Alshehri, S. A., Rabeh, M. A., El‐Mosallamy, A. E. M. K., Raey, M. A. E., & Gedaily, R. A. E. (2023) · Plants · doi:10.3390/plants12152813 · Cited by 10
“The preventive measurements include enforcing public health and infection control measurements and vaccination [15].”
BackgroundKalodimou, G., Jany, S., Freudenstein, A., Schwarz, J. H., Limpinsel, L., Rohde, C., Kupke, A., Becker, S., Volz, A., Tscherne, A., et al. (2023) · Viruses · doi:10.3390/v15051180 · Cited by 8
“However, there was no information on the efficacy of the mRNA vaccines when using an extended time interval, as the phase 3 trials for these vaccines were only tested at 3–4-week intervals [1,4].”
BackgroundNanoparticle-Based Tolerogenic Vaccines for the Treatment of Autoimmune Diseases: A Review
Nguyen, T. L., & Kim, J. (2022) · ACS Applied Nano Materials · doi:10.1021/acsanm.1c03726 · Cited by 9
Varicella‐Zoster virus reactivation following SARS‐CoV‐2 immunization in two patients with leukemia
Foster, C. E., Penella, A. D. V., Davis, A. L., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29191 · Cited by 8
Mancuso, R., Agostini, S., Citterio, L. A., Chiarini, D., Santangelo, M. A., & Clerici, M. (2022) · Vaccines · doi:10.3390/vaccines10101649 · Cited by 8
“BNT162b2 administration showed 95% effectiveness in the general population against the severe disease and a favorable safety profile [2], supporting the emergency use authorization of this vaccine both in the USA [3] and Europe [4] for ≥16 years old subjects and more recently for adolescent [5] and children as well [6…”
BackgroundJakubecz, C., Zhang, X. S., Woodson, S., Serra, A., & Abboud, H. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103785 · Cited by 8
Tompkins, L. K., Baggs, J. M., Myers, T. R., Gee, J. M., Marquez, P., Kennedy, S. B., Peake, D., Dua, D., Hause, A. M., Strid, P., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.073 · Cited by 8
“Clinical trials of these vaccines excluded persons with a history of COVID-19 [3,4], limiting our understanding of the risk of adverse events in this population.”
A third COVID-19 vaccine shot markedly boosts neutralizing antibody potency and breadthPreprint
Iketani, S., Liu, L., Nair, M. S., Mohri, H., Wang, M., Huang, Y., & Ho, D. D. (2021) · medRxiv · doi:10.1101/2021.08.11.21261670 · Cited by 8
Ganglioside-incorporating lipid nanoparticles as a polyethylene glycol-free mRNA delivery platform
Permana, Y. S., Jang, M., Yeom, K., Fagan, E., Kim, J. H., Choi, J., & Park, J. (2025) · Biomaterials Science · doi:10.1039/d4bm01360c · Cited by 9
Antibody response to the messenger RNA‐1273 vaccine (Moderna) in liver transplant recipients
Cuadrado, A., Barrio, M. D., Fortea, J. I., Amigo, L., Segundo, D. S., Rodriguez‐Cundin, M. P., Rebollo-Rodrigo, M. H., Fernández‐Santiago, R., Castillo, F., Achalandabaso, M., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1937 · Cited by 9
Antibody response after COVID-19 vaccine BNT162b2 on health care workers in Japan
Yoshimura, Y., Sasaki, H., Miyata, N., Miyazaki, K., & Tachikawa, N. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.08.008 · Cited by 8
“This is reasonable because BNT162b2 contains nucleoside-modified ribonucleic acid encoding the SARS-CoV-2 full-length spike protein [6].”
Second Dose of the BNT162b2 mRNA Vaccine in Greece: The Value of Timely Administration
Κοντοπούλου, Κ., Ainatzoglou, A., Nakas, C. T., Ifantidou, A. M., Gkounti, G., Antoniadou, E., Adamopoulos, V., Papadopoulos, N., & Papazisis, G. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.07.065 · Cited by 8
Ishitoku, M., Mokuda, S., Araki, K., Watanabe, H., Kohno, H., Sugimoto, T., Yoshida, Y., Sakaguchi, T., Masumoto, J., Hirata, S., et al. (2023) · Viruses · doi:10.3390/v15071498 · Cited by 10
Vaira, L. A., Podda, L., Doneddu, P., et al. (2021) · Journal of Stomatology Oral and Maxillofacial Surgery · doi:10.1016/j.jormas.2021.07.010 · Cited by 8
Park, J. Y., & Yi, S. Y. (2021) · Radiology Case Reports · doi:10.1016/j.radcr.2021.09.042 · Cited by 8
“[6] Polack FP , Thomas SJ , Kitchin N , Absalon J , Gurtman A , Lockhart S , et al.”
BackgroundSpecialist confirmed allergic reactions to COVID-19 mRNA vaccines at a mass vaccination site
Myles, I. A., Vinciguerra, J. S., & Premus, R. T. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.061 · Cited by 8
“Our results are consistent with previously reported data [4,8] and is reassuring regarding the overall safety of the vaccines.”
Unlocking the full therapeutic potential of lipid nanoparticles through extrahepatic delivery
Truong, H. Q., & Meng, F. (2025) · Nano Research · doi:10.26599/nr.2025.94907422 · Cited by 11
Tanislav, C., Rosenbauer, J., Zingel, R., & Kostev, K. (2022) · Public Health · doi:10.1016/j.puhe.2022.03.004 · Cited by 10
Kuzmina, A., Korovin, D., Cohen-Lass, I., Atari, N., Ottolenghi, A., Hu, P., Mandelboim, M., Rosental, B., Rosenberg, E., Diaz‐Griffero, F., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16750 · Cited by 8
Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants
Zhang, J., Xia, Y., Liu, X., & Liu, G. (2023) · Bioengineering · doi:10.3390/bioengineering10020148 · Cited by 8
“Despite significant protective efficacy against COVID-19 being reached (BNT162b2 conferred 95% protection [20], the mRNA-1273 vaccine howed 94.”
BackgroundInfluentialSoto, J., Linsley, C. S., Song, Y., Chen, B., Fang, J., Neyyan, J., Davila, R., Lee, B. S., Wu, B. M., & Li, S. (2023) · Nanomaterials · doi:10.3390/nano13172455 · Cited by 9
Modelling the impact of hybrid immunity on future COVID-19 epidemic waves
Le, T. P., Abell, I. R., Conway, E. J., Campbell, P. T., Hogan, A. B., Lydeamore, M., McVernon, J., Müeller, I., Walker, C. R., & Baker, C. M. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09282-4 · Cited by 11
“Both infection and vaccination provide immunity boosting effects to individuals [6, 7, 8, 9, 10, 11, 12, 13] and indirect benefits to others in the population, regardless of vaccination status, through reduction in onwards transmission [14].”
BackgroundThird dose of an mRNA COVID-19 vaccine for patients with multiple myeloma
Goldwater, M., Stampfer, S. D., Regidor, B. S. S., Bujarski, S. E., Jew, S. K., Chen, H., Xu, N., Kim, C. T., Kim, S., & Berenson, J. R. (2022) · Clinical Infection in Practice · doi:10.1016/j.clinpr.2022.100214 · Cited by 10
Single BNT162b2 vaccine dose produces seroconversion in under 60 s cohort
Shachor‐Meyouhas, Y., Hussein, K., Szwarcwort‐Cohen, M., Weissman, A., Mekel, M., Dabaja‐Younis, H., Hyams, G., Horowitz, N. A., Kaplan, M., & Halberthal, M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.016 · Cited by 8
“In the original BNT162b2 vaccine study, there was no difference in efficacy between age groups, so it may not have been different; but serological differences were not mentioned [5] except in a small phase I/II study [4] and another small study in Germany [18].”
Lund, L. C., Rahbek, M. T., Brown, P. D. N., Obel, N., Hallas, J., & Frederiksen, H. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14108 · Cited by 9
Cangemi, R., Franco, M. D., Angeloni, A., Zicari, A., Cardinale, V., Visentini, M., Antonelli, G., Napoli, A., Anastasi, E., Romiti, G. F., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060994 · Cited by 8
“Moreover, antibody levels were higher in women than in men and decreased with age at both T1 and T2; this observation is consistent with published data in other cohorts [9,12,13,15,19] and clinical trials [1].”
BackgroundResultTomioka, K., Uno, K., & Yamada, M. (2023) · Environmental Health and Preventive Medicine · doi:10.1265/ehpm.23-00061 · Cited by 8
Clonal structure and the specificity of vaccine-induced T cell response to SARS-CoV-2 Spike protein
Sheetikov, S. A., Khmelevskaya, A. A., Zornikova, K. V., Zvyagin, I. V., Shomuradova, A. S., Serdyuk, Y. V., Shakirova, N. T., Peshkova, I. O., Titov, A., Romaniuk, D. S., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1369436 · Cited by 10
Batac, A. L. R., Merrill, K. A., Askin, N., Golding, M. A., Abrams, E. M., Bégin, P., Ben‐Shoshan, M., Ladouceur, E., Roos, L. E., Protudjer, V., et al. (2023) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2023.100079 · Cited by 8
“Although no cases of anaphylaxis to the Pfizer COVID-19 vaccine were reported during the vaccine’s clinical trials, reactions have since been reported.(39,55) Utilizing the VAERS surveillance data from January 1, 2021, to April 30, 2021, Singh et al found the incidences of anaphylaxis to be 2.”
Gui, Y., Cao, Y., He, J., Zhao, C., Zheng, W., Qian, L., Cheng, J., Yu, C., Chen, Y., Lou, K., et al. (2023) · Life Metabolism · doi:10.1093/lifemeta/load019 · Cited by 7
Case Report: Retinal Vasculitis in Two Adolescents After COVID-19 Vaccination
Mohamed, S., Chan, C. K. M., Tsang, C. W., Szeto, S., Fong, A. H. C., Chan, J. C., & Wong, C. Y. (2022) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2022.2129694 · Cited by 8
“The mRNA vaccines have shown remarkable efficacy in reducing morbidity and mortality of severe COVID-19 infection, together with an excellent safety profile and only rare lifethreatening adverse events.(5,6) In the interests of transparency in reporting adverse events associated with COVID-19 vaccination, we describe…”
Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan
Chang, J., Chiou, J., Hung, C.-S., Liu, M.-C. J., Chang, H., Hong, S., Wang, C.-Y., Lin, Y., Hsieh, Y., Chung, C., et al. (2022) · Vaccines · doi:10.3390/vaccines10020312 · Cited by 8
“In contrast, mRNA-based boost SARS-CoV-2 vaccinations caused more severe and frequent systemic reactogenicity than the prime dose [3,10].”
BackgroundZhang, Y.-N., Paynter, J., Sou, C., Fourfouris, T., Wang, Y., Abraham, C., Ngo, T. A., Zhang, Y., He, L.-L., & Zhu, J. (2021) · bioRxiv · doi:10.1101/2021.03.26.437274 · Cited by 14
Burke, M. J., Scott, J. N. F., Minshull, T. C., Gao, Z., Manfield, I. W., Savic, S., Stockley, P. G., Calabrese, A. N., & Boyes, J. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102624 · Cited by 11
“Whilst vaccines proved remarkably successful at slowing SARS-CoV-2 transmission and preventing severe disease (1-3), they are not a panacea due to their typically high failure rate, potentially low efficacy and risk that they may not protect against all new variants.”
BackgroundYang, F., Tran, T. N.-A., Howerton, E., Boni, M. F., & Servadio, J. L. (2023) · BMC Medicine · doi:10.1186/s12916-023-03025-z · Cited by 10
“We assumed that mRNA vaccines have around 95% efficacy against infection for age > 18 based on previous studies [25, 26].”
Effectiveness of interventions to improve vaccine efficacy: a systematic review and meta-analysis
Aviraj, K. S., Wasnik, A., Gupta, L., Ranjan, A., & Suresh, H. (2025) · Systematic Reviews · doi:10.1186/s13643-025-02856-6 · Cited by 12
Statistical mechanics study of the introduction of a vaccine against COVID-19 disease
De-Leon, H., & Pederiva, F. (2021) · Physical review. E · doi:10.1103/physreve.104.014132 · Cited by 9
Zhang, Y., Li, J., Wang, Z., Kuang, Y., Li, S., & Wang, X. (2025) · Animal Diseases · doi:10.1186/s44149-025-00186-7 · Cited by 9
“…the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines were developed from sequence design to clinical approval approximately 10 months during the global COVID-19 pandemic, marking a historic milestone in the advancement of mRNA vaccine technology (Polack et al. 2020; Baden et al. 2021).”
COVID-19 Vaccination in Children: An Open Question
Bardanzellu, F., Campagnani, G., Pintus, M. C., Fanos, V., & Marcialis, M. A. (2021) · Current Pediatric Reviews · doi:10.2174/1573396318666211220093111 · Cited by 10
Distinguishing Immunologic and Behavioral Effects of Vaccination
Stensrud, M. J., Nevo, D., & Obolski, U. (2024) · Epidemiology · doi:10.1097/ede.0000000000001699 · Cited by 12
Progress of the Delta variant and erosion of vaccine effectiveness, a warning from UtahPreprint
Keegan, L. T., Truelove, S., & Lessler, J. (2021) · medRxiv · doi:10.1101/2021.08.09.21261554 · Cited by 8
Emerging Omicron subvariants evade neutralizing immunity elicited by vaccine or BA.1/BA.2 infection
Chen, Z., Li, J., Zheng, J., Jin, Y., Zhang, Y., Tang, F., Li, J., Cheng, H., Jiang, L., Wen, H., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28539 · Cited by 7
Retrospective record review on timing of COVID‐19 vaccination and cardiac surgery
Ho, J. Y. K., Siu, I. C. H., Ng, K. H. L., et al. (2022) · Journal of Cardiac Surgery · doi:10.1111/jocs.16883 · Cited by 8
Safety of the BNT162b2 mRNA COVID-19 vaccine in patients with familial Mediterranean fever
Shechtman, L., Lahad, K., Livneh, A., Grossman, C., Druyan, A., Giat, E., Lidar, M., Freund, S., Manor, U., Pomerantz, A., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac131 · Cited by 8
Yamamoto, S., Matsuda, K., Maeda, K., Oshiro, Y., Inamura, N., Mizoue, T., Konishi, M., Takeuchi, J. S., Horii, K., Ozeki, M., et al. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08272-2 · Cited by 9
“Background Clinical trials showed that the mRNA-based vaccine was highly effective in reducing the risk of morbidity and mortality of coronavirus disease 2019 (COVID-19) [1].”
BackgroundThe coverage of medical injuries in company trial informed consent forms
Healy, D., Roux, A. G., & Dressen, B. (2023) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-220043 · Cited by 10
Frahm, N., Fneish, F., Ellenberger, D., Haas, J., Löbermann, M., Peters, M., Pöhlau, D., Röper, A.-L., Schilling, S., Stahmann, A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113640 · Cited by 10
Killeen, T., Saxer, R. T., & Kermer, V. (2023) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-023-00652-y · Cited by 9
“Early phase results were promising [10, 11] and both programs proceeded to large-scale pivotal trials, which met their primary efficacy endpoints in December 2020 [1, 9].”
BackgroundInfluentialLong‐term effects of SARS‐CoV ‐2 vaccination in the nursing home setting
Rivasi, G., Bulgaresi, M., Bandinelli, C., Balzi, D., Tarantini, F., Tognelli, S., Lorini, C., Buscemi, P., Baggiani, L., Landini, G., et al. (2022) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17773 · Cited by 10
“The BNT162b2 mRNA vaccine has proven effective in preventing new SARS-CoV-2 infections and severe COVID-19 disease, with protective effect becoming evident from 2 weeks after the first dose.(1) What remains unclear, however, is how long the vaccine provides protection against COVID-19 and against SARS-CoV-2 transmissi…”
Advances in mRNA-LNP lung-targeted delivery strategies
Liu, X., Ji, S., Cai, Y., Yang, F., You, J., & Luo, L. (2025) · Microstructures · doi:10.20517/microstructures.2024.172 · Cited by 14
The precision paradox: How personalized medicine increases uncertainty
Vogt, H. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0005 · Cited by 14
Heiser, B. J., Lewis, M. M., Zerankeshi, M. M., Netemeyer, E. K., Hernandez, A. M., Marras, A. E., & Ghosh, D. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00061k · Cited by 18
Real-time identification of epistatic interactions in SARS-CoV-2 from large genome collections
Innocenti, G., Obara, M., Costa, B., Jacobsen, H., Katzmarzyk, M., Čičin‐Šain, L., Kalinke, U., & Galardini, M. (2024) · Genome biology · doi:10.1186/s13059-024-03355-y · Cited by 14
“Given the successes of SARS-CoV-2 genome sequencing in tracking the emergence and spread of variants and to develop groundbreaking vaccines [16], it is hard to imagine it not becoming a routine tool in handling current and future epidemics [17].”
BackgroundChen, C., Chen, C., Cao, L., Fang, J., & Xiao, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112022 · Cited by 13
Werner, F., Zeschick, N., Kühlein, T., Steininger, P. A., Überla, K., Kaiser, I., Sebastião, M., Hueber, S., & Warkentin, L. (2023) · BMC Medicine · doi:10.1186/s12916-023-03064-6 · Cited by 10
RNA therapeutics in cardiovascular medicine
Damase, T. R., & Cooke, J. P. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001210 · Cited by 9
Nanotechnologically Relevant Aspects of COVID-19 Vaccines
Batley, R. J., & Chandra, S. (2023) · Frontiers in Bioscience-Elite · doi:10.31083/j.fbe1501007 · Cited by 9
The role of childrens’ vaccination for COVID-19—Pareto-optimal allocations of vaccines
Gavish, N., & Katriel, G. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009872 · Cited by 8
“By construction, this combination of parameters gives rise to an overall reduction of 95% in the risk of a vaccinated individual to develop severe disease as estimated in controlled studies [24] and analysis of real-world data [25].”
Scher, I., Berjohn, C. M., Byrne, C., Colombo, R. E., Colombo, C. J., Edwards, M., Ewers, E. C., Ganesan, A., Jones, M. U., Larson, D. T., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac314 · Cited by 9
Gounant, V., Ferré, V., Soussi, G., Charpentier, C., Flament, H., Fidouh, N., Collin, G., Namour, C., Assoun, S., Bizot, A., et al. (2021) · medRxiv · doi:10.1101/2021.08.12.21261806 · Cited by 9
Public Figure Vaccination Rhetoric and Vaccine Hesitancy: Retrospective Twitter Analysis
Honcharov, V., Li, J., Sierra, M., Rivadeneira, N. A., Olazo, K., Nguyen, T. T. X., Mackey, T. K., & Sarkar, U. (2023) · JMIR Infodemiology · doi:10.2196/40575 · Cited by 9
Global landscape of COVID-19 research: a visualization analysis of randomized clinical trials
Zyoud, S. H. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01254-3 · Cited by 11
“Furthermore, real-life data from vaccine deployments in many countries provide convincing evidence that vaccines can significantly reduce hospitalization, serious illness, and mortality rates associated with COVID-19 [84, 121, 122].”
Optimal COVID-19 Vaccine Sharing Between Two Nations That Also Have Extensive Travel Exchanges
Huntingford, C., Rawson, T., & Bonsall, M. B. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.633144 · Cited by 6
“An early assessment of the Oxford AstraZeneca vaccine suggests it to be 70% effective (27) and the Pfizer vaccine is reported as being 95% effective (28).”
BackgroundChamie-Quintero, J. J., Hibberd, J. A., & Scheim, D. E. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3765018 · Cited by 10
Li, H., Cai, D., Jiang, D., Li, X., Liao, X., Liu, D., Liu, Z., Zhu, P., Yin, G., Ming, J., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28434 · Cited by 7
COVID-19, G. D. T. M. D. F. S. E. M. D. L. T. V. C. R. C. L. V. F. A. (2021) · Neurología · doi:10.1016/j.nrl.2021.05.001 · Cited by 7
Advancing single-shot vaccine design through AI and computational models
Seetharam, G. U. D. E., ABBURI, S. K., Punith Kumar, G. A. L. I., & GORLAGUNTA, S. (2025) · Translational and Regulatory Sciences · doi:10.33611/trs.2025-002 · Cited by 11
Jeantin, L., Abdi, B., Soulié, C., Sterlin, D., Maillart, É., Beigneux, Y., Hippolyte, A., Belin, L., Marcelin, A., Pourcher, V., et al. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2023-331770 · Cited by 8
The COVID-19 Vaccine and the Black Community: Addressing the Justified Questions
Laurencin, C. T., Valantine, H. A., Yancy, C. W., Jones, C. P., & Bright, C. M. (2021) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-021-01082-9 · Cited by 9
A case of herpes zoster ophthalmicus after third dose of Comirnaty ( BNT162b2 mRNA ) vaccine
Martora, F., Fabbrocini, G., & Picone, V. (2022) · Dermatologic Therapy · doi:10.1111/dth.15411 · Cited by 8
Huiberts, A. J., Hoeve, C. E., Kooijman, M. N., de Melker, H. E., Hahné, S. J. M., Grobbee, D. E., van Binnendijk, R. S., den Hartog, G., van de Wijgert, J. H. H. M., van den Hof, S., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-085388 · Cited by 14
Albayat, S. S., Almaslamani, M., Al‐Romaihi, H. E., Khogali, H., Mundodan, J. M., Joury, J., & Haridy, H. (2023) · Vaccines · doi:10.3390/vaccines11050953 · Cited by 11
“It is worth noting that vaccine effectiveness was defined differently among studies; for example, it was often derived using the percentage reduction in infection hazard ratios or calculated as 1 minus the ratio of confirmed COVID-19 cases in the vaccine versus placebo groups [27,28,66].”
BackgroundMethodSchröder, D., Müllenmeister, C., Heinemann, S., Hummers, E., Klawonn, F., Vahldiek, K., Dopfer‐Jablonka, A., Steffens, S., Mikuteit, M., Niewolik, J., et al. (2023) · Health Psychology and Behavioral Medicine · doi:10.1080/21642850.2023.2249534 · Cited by 9
“A full COVID-19 vaccination was defined as 14 days after two vaccination shots (BNT162b2 (Polack et al., 2020), mRNA-1273 (Baden et al., 2021) or AZD1222 (Voysey et al., 2021)) or after one in case Ad26.”
COVID-19 Vaccine: Review of the Mechanism of Action of Different Types of Vaccine
Wong, L.-A., Yap, C. G., Jahan, N. K., & Pillai, N. (2022) · OALib · doi:10.4236/oalib.1108624 · Cited by 13
Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
Fang, Z., Peng, L., Lucas, C. G. D. O., Lin, Q., Zhou, L., Yang, L., Feng, Y., Ren, P., Renauer, P. A., Monteiro, V. S., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00435-w · Cited by 7
Flow-NMR as a Process-Monitoring Tool for mRNA IVT Reaction
Sarkar, A., Dong, G., Quaglia-Motta, J., & Sackett, K. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.11.021 · Cited by 9
Ali, S., Nedvědová, Š., Badshah, G., Afridi, M. S., Abdullah, Dutra, L. M., Ali, U., Faria, S. G. D., Soares, F. L. F., Rahman, R. U., et al. (2022) · Current Research in Immunology · doi:10.1016/j.crimmu.2022.08.006 · Cited by 8
“Among ARs, the rate of VITT has was shown to be due to the activated platelets antibodies against platelet factor-4 (Smith et al., 2021).”
InfluentialUnderstanding COVID-19 Epidemics: A Multi-Scale Modeling Approach
Aguiar, M., Anam, V., Cusimano, N., et al. (2022) · Modeling and simulation in science, engineering & technology · doi:10.1007/978-3-030-96562-4_2 · Cited by 8
Tokumitsu, K., Sugawara, N., Tabuchi, T., & Yasui‐Furukori, N. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05899-6 · Cited by 10
“COVID-19 vaccines have the potential to diminish the risk of contracting and developing severe COVID-19 [31].”
BackgroundSubramani, C., Meyer, M., Hyde, M. A., Comeaux, M. E., Hao, H., Crowe, J. E., Popov, V. L., Thaker, H. M., Himansu, S., Carfí, A., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194586 · Cited by 9
“The success of mRNA vaccines in combating the SARS-CoV-2 pandemic (29, 30) has accelerated the development of mRNA vaccines against an array of viruses such as HIV-1 (31), influenza virus (32), respiratory syncytial virus (33), Andes virus (ANDV) (34), Lassa virus (35), and Ebola virus (36),…”
Corrao, G., Bertolaso, G., Pavesi, G., & Moratti, L. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19031073 · Cited by 9
“Few studies have investigated the persistence of vaccine-dependent protection by direct approaches (clinical outcomes assessment [12,16,31,32]), rather than surrogate-based (neutralizing antibody assay [17,33,34]) approaches.”
BackgroundNikoloudis, A., Neumann, I. J., Buxhofer‐Ausch, V., Machherndl‐Spandl, S., Binder, M., Kaynak, E., Milanov, R., Nocker, S., Stiefel, O., Straßl, I., et al. (2023) · Vaccines · doi:10.3390/vaccines11101534 · Cited by 7
Exploring the Effects of Vitamin D and Vitamin A Levels on the Response to COVID-19 Vaccine
Kofahi, H. M., Badran, B. R., Nimer, R. M., Atoom, A. M., & Hersh, S. M. A. (2023) · Vaccines · doi:10.3390/vaccines11091509 · Cited by 8
“Phase III clinical trial results showed that the efficacy of BNT162b2 vaccine in preventing COVID-19 is 95% [39].”
Background
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.